Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 12/2007

01-12-2007 | Original Article

Robust anti-tumor immunity and memory in Rag-1-deficient mice following adoptive transfer of cytokine-primed splenocytes and tumor CD80 expression

Authors: Priyadarshini L. Ganesan, Stephen I. Alexander, Debbie Watson, Grant J. Logan, Geoff Y. Zhang, Ian E. Alexander

Published in: Cancer Immunology, Immunotherapy | Issue 12/2007

Login to get access

Abstract

Successful immunotherapy of solid tumors has proven difficult to achieve. The aim of the current study was to further investigate the effects of peripheral CD80-mediated co-stimulation on the efficacy of polyclonal anti-tumor effector CTL in an adoptive transfer model. Splenocytes obtained from wild-type mice immunized with CD80-transduced EL4 tumor cells were expanded in vitro in the presence of either IL-12 or IL-15 and irradiated CD80-transduced EL4 tumor cells. Polyclonal CD8 T cells were the major subset in the effector population. Primed effector cells were adoptively transferred into immuno-deficient Rag-1-deficient mice which were then challenged with syngeneic vector-control or CD80-transduced EL4 tumor cells. Expression of CD80 enhanced the elimination of EL4 tumors and mouse survival. Both IL-12 and IL-15 cultured cells had enhanced cytotoxicity. Importantly, anti-tumor memory was maintained without tumor evasion following re-challenge with either CD80-transduced and vector-control EL4 cells. We also show, using antibody-mediated depletion, that endogenous NK cells present in Rag-1-deficent mice exert anti-EL4 tumor activity that is enhanced by CD80 expression. Collectively these data show that peripheral co-stimulation by tumor expression of CD80 results in enhanced anti-tumor efficacy of NK and polyclonal effector T cells, and suggest that TCR repertoire diversity helps protect against tumor escape and provides memory with resultant robust immunity to subsequent tumor challenge irrespective of CD80 status.
Literature
1.
go back to reference Azuma M, Cayabyab M, Buck D, Phillips JH, Lanier LL (1992) Involvement of CD28 in MHC-unrestricted cytotoxicity mediated by a human natural killer leukemia cell line. J Immunol 149:1115PubMed Azuma M, Cayabyab M, Buck D, Phillips JH, Lanier LL (1992) Involvement of CD28 in MHC-unrestricted cytotoxicity mediated by a human natural killer leukemia cell line. J Immunol 149:1115PubMed
2.
go back to reference Bai XF, Bender J, Liu J, Zhang H, Wang Y, Li O, Du P, Zheng P, Liu Y (2001) Local costimulation reinvigorates tumor-specific cytolytic t lymphocytes for experimental therapy in mice with large tumor burdens. J Immunol 167:3936PubMed Bai XF, Bender J, Liu J, Zhang H, Wang Y, Li O, Du P, Zheng P, Liu Y (2001) Local costimulation reinvigorates tumor-specific cytolytic t lymphocytes for experimental therapy in mice with large tumor burdens. J Immunol 167:3936PubMed
3.
go back to reference Bai XF, Liu J, Li O, Zheng P,Liu Y (2003) Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes. J Clin Invest 111:1487PubMedCrossRef Bai XF, Liu J, Li O, Zheng P,Liu Y (2003) Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes. J Clin Invest 111:1487PubMedCrossRef
4.
go back to reference Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glimcher LH (1993) Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci USA 90:5687PubMedCrossRef Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glimcher LH (1993) Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci USA 90:5687PubMedCrossRef
5.
go back to reference Bertolino P, Trescol-Biemont MC,Rabourdin-Combe C (1998) Hepatocytes induce functional activation of naive CD8+ T lymphocytes but fail to promote survival. Eur J Immunol 28:221PubMedCrossRef Bertolino P, Trescol-Biemont MC,Rabourdin-Combe C (1998) Hepatocytes induce functional activation of naive CD8+ T lymphocytes but fail to promote survival. Eur J Immunol 28:221PubMedCrossRef
6.
go back to reference Carayannopoulos LN, Naidenko OV, Fremont DH, Yokoyama WM (2002) Cutting edge: murine UL16-binding protein-like transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D. J Immunol 169:4079PubMed Carayannopoulos LN, Naidenko OV, Fremont DH, Yokoyama WM (2002) Cutting edge: murine UL16-binding protein-like transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D. J Immunol 169:4079PubMed
7.
go back to reference Cerwenka A, Lanier LL (2001) Ligands for natural killer cell receptors: redundancy or specificity. Immunol Rev 181:158PubMedCrossRef Cerwenka A, Lanier LL (2001) Ligands for natural killer cell receptors: redundancy or specificity. Immunol Rev 181:158PubMedCrossRef
8.
go back to reference Chambers BJ, Salcedo M, Ljunggren HG (1996) Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1). Immunity 5:311PubMedCrossRef Chambers BJ, Salcedo M, Ljunggren HG (1996) Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1). Immunity 5:311PubMedCrossRef
9.
10.
go back to reference Chen L (2004) Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4:336PubMedCrossRef Chen L (2004) Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4:336PubMedCrossRef
11.
go back to reference Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS (1992) Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093PubMedCrossRef Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS (1992) Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093PubMedCrossRef
12.
go back to reference Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellstrom I, Hellstrom KE (1994) Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 179:523PubMedCrossRef Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellstrom I, Hellstrom KE (1994) Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 179:523PubMedCrossRef
13.
go back to reference Croft M (2003) Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 3:609PubMedCrossRef Croft M (2003) Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 3:609PubMedCrossRef
14.
go back to reference Curtsinger JM, Lins DC, Mescher MF (2003) Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med 197:1141PubMedCrossRef Curtsinger JM, Lins DC, Mescher MF (2003) Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med 197:1141PubMedCrossRef
15.
go back to reference Demirci G, Li XC (2004) IL-2 and IL-15 exhibit opposing effects on Fas mediated apoptosis. Cell Mol Immunol 1:123PubMed Demirci G, Li XC (2004) IL-2 and IL-15 exhibit opposing effects on Fas mediated apoptosis. Cell Mol Immunol 1:123PubMed
16.
go back to reference Diefenbach A, Jensen ER, Jamieson AM, Raulet DH (2001) Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413:165PubMedCrossRef Diefenbach A, Jensen ER, Jamieson AM, Raulet DH (2001) Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413:165PubMedCrossRef
17.
go back to reference Dorshkind K, Pollack SB, Bosma MJ, Phillips RA (1985) Natural killer (NK) cells are present in mice with severe combined immunodeficiency (scid). J Immunol 134:3798PubMed Dorshkind K, Pollack SB, Bosma MJ, Phillips RA (1985) Natural killer (NK) cells are present in mice with severe combined immunodeficiency (scid). J Immunol 134:3798PubMed
18.
19.
go back to reference Heath WR, Carbone FR (2001) Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 19:47PubMedCrossRef Heath WR, Carbone FR (2001) Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 19:47PubMedCrossRef
20.
go back to reference Hodge JW, Abrams S, Schlom J, Kantor JA (1994) Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 54:5552PubMed Hodge JW, Abrams S, Schlom J, Kantor JA (1994) Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 54:5552PubMed
21.
go back to reference Kelly JM, Takeda K, Darcy PK, Yagita H, Smyth MJ (2002) A role for IFN-gamma in primary and secondary immunity generated by NK cell-sensitive tumor-expressing CD80 in vivo. J Immunol 168:4472PubMed Kelly JM, Takeda K, Darcy PK, Yagita H, Smyth MJ (2002) A role for IFN-gamma in primary and secondary immunity generated by NK cell-sensitive tumor-expressing CD80 in vivo. J Immunol 168:4472PubMed
23.
go back to reference Lenschow DJ, Walunas TL, Bluestone JA (1996) CD28/B7 system of T cell costimulation. Annu Rev Immunol 14:233PubMedCrossRef Lenschow DJ, Walunas TL, Bluestone JA (1996) CD28/B7 system of T cell costimulation. Annu Rev Immunol 14:233PubMedCrossRef
24.
go back to reference Li Y, McGowan P, Hellstrom I, Hellstrom KE, Chen L (1994) Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol 153:421PubMed Li Y, McGowan P, Hellstrom I, Hellstrom KE, Chen L (1994) Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol 153:421PubMed
25.
go back to reference Liu Y, Janeway CA Jr (1992) Cells that present both specific ligand and costimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T cells. Proc Natl Acad Sci USA 89:3845PubMedCrossRef Liu Y, Janeway CA Jr (1992) Cells that present both specific ligand and costimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T cells. Proc Natl Acad Sci USA 89:3845PubMedCrossRef
26.
go back to reference Logan GJ, Spinoulas A, Alexander SI, Smythe JA, Alexander IE (2004) CD4 expression on EL4 cells as an epiphenomenon of retroviral transduction and selection. Immunol Cell Biol 82:132PubMedCrossRef Logan GJ, Spinoulas A, Alexander SI, Smythe JA, Alexander IE (2004) CD4 expression on EL4 cells as an epiphenomenon of retroviral transduction and selection. Immunol Cell Biol 82:132PubMedCrossRef
27.
go back to reference Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE (1992) RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68:869PubMedCrossRef Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE (1992) RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68:869PubMedCrossRef
28.
go back to reference Mueller YM, Bojczuk PM, Halstead ES, Kim AH, Witek J, Altman JD, Katsikis PD (2003) IL-15 enhances survival and function of HIV-specific CD8+ T cells. Blood 101:1024PubMedCrossRef Mueller YM, Bojczuk PM, Halstead ES, Kim AH, Witek J, Altman JD, Katsikis PD (2003) IL-15 enhances survival and function of HIV-specific CD8+ T cells. Blood 101:1024PubMedCrossRef
29.
go back to reference Probst HC, McCoy K, Okazaki T, Honjo T, van den Broek M. (2005) Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol 6:280PubMedCrossRef Probst HC, McCoy K, Okazaki T, Honjo T, van den Broek M. (2005) Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol 6:280PubMedCrossRef
30.
go back to reference Refaeli Y, Van Parijs L, London CA, Tschopp J, Abbas AK (1998) Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 8:615PubMedCrossRef Refaeli Y, Van Parijs L, London CA, Tschopp J, Abbas AK (1998) Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 8:615PubMedCrossRef
31.
go back to reference Roberts AI, Lee L, Schwarz E, Groh V, Spies T, Ebert EC, Jabri B (2001) NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J Immunol 167:5527PubMed Roberts AI, Lee L, Schwarz E, Groh V, Spies T, Ebert EC, Jabri B (2001) NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J Immunol 167:5527PubMed
32.
34.
go back to reference Taieb J, Chaput N, Menard C, Apetoh L, Ullrich E, Bonmort M, Pequignot M, Casares N, Terme M, Flament C, Opolon P, Lecluse Y, Metivier D, Tomasello E, Vivier E, Ghiringhelli F, Martin F, Klatzmann D, Poynard T, Tursz T, Raposo G, Yagita H, Ryffel B, Kroemer G, Zitvogel L (2006) A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 12:214PubMedCrossRef Taieb J, Chaput N, Menard C, Apetoh L, Ullrich E, Bonmort M, Pequignot M, Casares N, Terme M, Flament C, Opolon P, Lecluse Y, Metivier D, Tomasello E, Vivier E, Ghiringhelli F, Martin F, Klatzmann D, Poynard T, Tursz T, Raposo G, Yagita H, Ryffel B, Kroemer G, Zitvogel L (2006) A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 12:214PubMedCrossRef
35.
go back to reference Toes RE, Ossendorp F, Offringa R, Melief CJ (1999) CD4 T cells and their role in antitumor immune responses. J Exp Med 189:753PubMedCrossRef Toes RE, Ossendorp F, Offringa R, Melief CJ (1999) CD4 T cells and their role in antitumor immune responses. J Exp Med 189:753PubMedCrossRef
36.
go back to reference Townsend SE, Allison JP (1993) Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259:368PubMedCrossRef Townsend SE, Allison JP (1993) Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259:368PubMedCrossRef
37.
go back to reference Trzonkowski P, Szmit E, Mysliwska J, Dobyszuk A, Mysliwski A (2004) CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction. Clin Immunol 112:258PubMedCrossRef Trzonkowski P, Szmit E, Mysliwska J, Dobyszuk A, Mysliwski A (2004) CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction. Clin Immunol 112:258PubMedCrossRef
38.
go back to reference Walker LS, Chodos A, Eggena M, Dooms H,Abbas AK (2003) Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J Exp Med 198:249PubMedCrossRef Walker LS, Chodos A, Eggena M, Dooms H,Abbas AK (2003) Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J Exp Med 198:249PubMedCrossRef
39.
go back to reference Watson D, Zhang GY, Sartor M, Alexander SI (2004) “Pruning” of alloreactive CD4+ T cells using 5- (and 6-)carboxyfluorescein diacetate succinimidyl ester prolongs skin allograft survival. J Immunol 173:6574PubMed Watson D, Zhang GY, Sartor M, Alexander SI (2004) “Pruning” of alloreactive CD4+ T cells using 5- (and 6-)carboxyfluorescein diacetate succinimidyl ester prolongs skin allograft survival. J Immunol 173:6574PubMed
40.
go back to reference Wu TC, Huang AY, Jaffee EM, Levitsky HI, Pardoll DM (1995) A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med 182:1415PubMedCrossRef Wu TC, Huang AY, Jaffee EM, Levitsky HI, Pardoll DM (1995) A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med 182:1415PubMedCrossRef
41.
go back to reference Yeh KY, Pulaski BA, Woods ML, McAdam AJ, Gaspari AA, Frelinger JG, Lord EM (1995) B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinoma. Cell Immunol 165:217PubMedCrossRef Yeh KY, Pulaski BA, Woods ML, McAdam AJ, Gaspari AA, Frelinger JG, Lord EM (1995) B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinoma. Cell Immunol 165:217PubMedCrossRef
42.
go back to reference Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, Lanier LL (2004) Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J Immunol 173:3716PubMed Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, Lanier LL (2004) Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J Immunol 173:3716PubMed
Metadata
Title
Robust anti-tumor immunity and memory in Rag-1-deficient mice following adoptive transfer of cytokine-primed splenocytes and tumor CD80 expression
Authors
Priyadarshini L. Ganesan
Stephen I. Alexander
Debbie Watson
Grant J. Logan
Geoff Y. Zhang
Ian E. Alexander
Publication date
01-12-2007
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 12/2007
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-007-0339-7

Other articles of this Issue 12/2007

Cancer Immunology, Immunotherapy 12/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine